Table 3.

Risk factors for poor visual acuity at presentation in eyes affected with JIA-related uveitis

Characteristic	20/50 or worse		20/200 or worse
	Crude OR (95% CI, P)*	Adjusted OR (95% CI, P)†	Crude OR (95% CI, P)*	Adjusted OR (95% CI, P)†
Age at uveitis diagnosis	0.98 (0.94-1.03, 0.44)		0.93 (0.87-0.99, 0.03)
Gender (male vs female)	0.92 (0.46-1.85, 0.83)		1.06 (0.44-2.56, 0.88)	3.70 (0.92-14.3, 0.07)
Race (other vs white)	1.41 (0.92-2.16, 0.12)		1.28 (0.82-1.98, 0.28)
Bilateral disease	2.19 (0.81-5.92, 0.12)		4.33 (0.95-9.65, 0.06)
Duration of uveitis (years)	3.77 (1.74-8.17, 0.001)		3.38 (1.37-8.29, 0.008)
Persistent oligoarthritis	1.36 (0.54-3.44, 0.51)		0.84 (0.30-2.15, 0.66)
ANA-positive	3.40 (1.27-9.08, 0.02)		2.71 (0.85-8.61, 0.09)
Posterior synechiae	3.51 (1.62-7.64, 0.002)		2.23 (1.00-5.14, 0.05)	8.56 (1.67-43.8, 0.01)
Band keratopathy (peripheral)	3.17 (1.84-5.46, <0.001)		3.51 (2.10-5.87, 0.001)
Anterior chamber flare	3.23 (1.96-5.32, <0.001)	7.16 (1.48-34.6, 0.01)	2/03 (1.28-3.21, 0.003)	1.82 (1.04-3.18, 0.04)
Abnormal IOP (<5 or >21 mm Hg)	3.28 (1.44-7.42, 0.004)		4.58 (1.90-11.03, 0.001)	2.56 (0.81-8.11, 0.11)
Prior hypotony	13.26 (2.62-67.07, 0.002)		8.55 (2.15-33.90, 0.002)
Prior ocular hypertension	2.50 (1.01-6.19, 0.05)	4.26 (0.71-25.5, 0.11)	2.17 (0.79-5.94, 0.13)
Prior systemic corticosteroids	5.08 (2.33-11.04, <0.001)	4.43 (0.88-22.2, 0.07)	4.32 (1.84-10.20, 0.001)
Prior methotrexate	1.26 (0.53-3.01, 0.60)		1.86 (0.74-4.73, 0.19)
Prior surgery	9.16 (3.94-21.31, <0.001)	12.11 (2.44-21, 0.008)	7.27 (2.99-17.66, 0.001)	12.92 (1.90-88.1, 0.009)
Systemic corticosteroids at presentation	3.00 (0.99-9.07, 0.05)		6.41 (2.06-19.98, 0.001)
Methotrexate at presentation	1.06 (0.42-2.66, 0.90)	0.13 (0.01-0.96, 0.05)	1.83 (0.69-4.81, 0.22)

JIA = juvenile idiopathic arthritis

^*OR = odds ratio (95% Confidence interval, P-value)